T1	Outcomes 44 52	migraine
T2	Outcomes 153 178	tolerability and efficacy
T3	Outcomes 437 569	Headache severity, presence or absence of associated symptoms, and functional disability were assessed over a 4-hour postdose period
T4	Outcomes 579 593	adverse events
T5	Outcomes 642 679	pain-free status at 2 hours postdose.
T6	Outcomes 752 766	adverse events
T7	Outcomes 844 907	dry mouth, dizziness, asthenia/fatigue, nausea, and somnolence.
T8	Outcomes 935 944	pain-free
T9	Outcomes 1022 1061	percentage of patients with pain relief
T10	Outcomes 1076 1098	predose pain intensity
T11	Outcomes 1184 1206	Placebo response rates
T12	Outcomes 1353 1374	functional disability
T13	Outcomes 1399 1405	nausea
T14	Outcomes 1541 1552	pain relief
T15	Outcomes 1704 1717	response rate
T16	Outcomes 1792 1815	tolerated and effective
